Antibody responses against influenza A decline with successive years of annual influenza vaccination.

Influenza vaccine effectiveness and immunogenicity can be compromised with repeated vaccination. We assessed immunological markers in a cohort of healthcare workers (HCW) from six public hospitals around Australia during 2020-2021. Sera were collected pre-vaccination and ~14 and ~180 days post-vaccination and assessed in haemagglutination inhibition assay against egg-grown vaccine and equivalent cell-grown viruses.

The 24-kDa subunit of mitochondrial complex I regulates growth, microsclerotia development, stress tolerance, and virulence in Verticillium dahliae.

Background: The complete mitochondrial respiratory chain is a precondition for maintaining cellular energy supply, development, and metabolic balance. Due to the evolutionary differentiation of complexes and the semi-autonomy of mitochondria, respiratory chain subunits have become critical targets for crop improvement and fungal control. In fungi, mitochondrial complex I mediates growth and metabolism.

The acyl-CoA-binding protein VdAcb1 is essential for carbon starvation response and contributes to virulence in .

Unlabelled: In the face of carbon, nitrogen, and phosphorus starvation, microorganisms have evolved adaptive mechanisms to maintain growth. In a previous study, we identified a protein predicted to contain acyl-CoA-binding domains in the plant pathogenic fungus . The predicted protein, designated VdAcb1, possesses an atypical signal peptide.

Implications of the apparent extinction of B/Yamagata-lineage human influenza viruses.

Following the onset of the COVID-19 pandemic in 2020, the number of influenza viruses circulating globally fell to historically low numbers. Although influenza A and B/Victoria lineage viruses returned to normal patterns by 2022, B/Yamagata-lineage viruses have not been identified since 2020. The implications of the apparent extinction of this lineage of viruses on vaccine composition, and the risk of their re-introduction into the human population are discussed.

The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.

Objectives: PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

Methods: Immunocompetent adults who had received two doses of BNT162b2 and any licensed COVID-19 booster at least three months prior were eligible.